Logo image of ACRV

ACRIVON THERAPEUTICS INC (ACRV) Stock Fundamental Analysis

NASDAQ:ACRV - Nasdaq - US0048901096 - Common Stock - Currency: USD

1.81  -0.04 (-2.16%)

After market: 1.79 -0.02 (-1.1%)

Fundamental Rating

3

ACRV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. ACRV has a great financial health rating, but its profitability evaluates not so good. ACRV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACRV had negative earnings in the past year.
In the past year ACRV has reported a negative cash flow from operations.
In the past 5 years ACRV always reported negative net income.
ACRV had a negative operating cash flow in each of the past 5 years.
ACRV Yearly Net Income VS EBIT VS OCF VS FCFACRV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -40.98%, ACRV perfoms like the industry average, outperforming 55.46% of the companies in the same industry.
With a decent Return On Equity value of -45.57%, ACRV is doing good in the industry, outperforming 67.43% of the companies in the same industry.
Industry RankSector Rank
ROA -40.98%
ROE -45.57%
ROIC N/A
ROA(3y)-33.95%
ROA(5y)-71.69%
ROE(3y)-37.89%
ROE(5y)-107.72%
ROIC(3y)N/A
ROIC(5y)N/A
ACRV Yearly ROA, ROE, ROICACRV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACRV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACRV Yearly Profit, Operating, Gross MarginsACRV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

ACRV has more shares outstanding than it did 1 year ago.
ACRV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACRV Yearly Shares OutstandingACRV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
ACRV Yearly Total Debt VS Total AssetsACRV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -0.18, we must say that ACRV is in the distress zone and has some risk of bankruptcy.
ACRV has a better Altman-Z score (-0.18) than 64.08% of its industry peers.
ACRV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.18
ROIC/WACCN/A
WACCN/A
ACRV Yearly LT Debt VS Equity VS FCFACRV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

ACRV has a Current Ratio of 10.55. This indicates that ACRV is financially healthy and has no problem in meeting its short term obligations.
ACRV has a Current ratio of 10.55. This is amongst the best in the industry. ACRV outperforms 80.99% of its industry peers.
A Quick Ratio of 10.55 indicates that ACRV has no problem at all paying its short term obligations.
ACRV has a Quick ratio of 10.55. This is amongst the best in the industry. ACRV outperforms 81.16% of its industry peers.
Industry RankSector Rank
Current Ratio 10.55
Quick Ratio 10.55
ACRV Yearly Current Assets VS Current LiabilitesACRV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

ACRV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.62%, which is quite good.
EPS 1Y (TTM)10.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 1.40% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-17.79%
EPS Next 2Y-8.7%
EPS Next 3Y-4.25%
EPS Next 5Y1.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACRV Yearly Revenue VS EstimatesACRV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ACRV Yearly EPS VS EstimatesACRV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACRV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACRV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRV Price Earnings VS Forward Price EarningsACRV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRV Per share dataACRV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as ACRV's earnings are expected to decrease with -4.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.7%
EPS Next 3Y-4.25%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACRV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACRIVON THERAPEUTICS INC

NASDAQ:ACRV (4/17/2025, 8:00:45 PM)

After market: 1.79 -0.02 (-1.1%)

1.81

-0.04 (-2.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)N/A N/A
Inst Owners57.6%
Inst Owner Change0%
Ins Owners9.71%
Ins Owner Change-1.97%
Market Cap56.74M
Analysts82.5
Price Target16.7 (822.65%)
Short Float %3.96%
Short Ratio14.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.89%
Min EPS beat(2)-0.13%
Max EPS beat(2)11.91%
EPS beat(4)3
Avg EPS beat(4)10.6%
Min EPS beat(4)-0.13%
Max EPS beat(4)15.33%
EPS beat(8)6
Avg EPS beat(8)5.64%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-22.43%
PT rev (3m)-24.03%
EPS NQ rev (1m)6.61%
EPS NQ rev (3m)9.17%
EPS NY rev (1m)-0.96%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-51.77%
Revenue NY rev (3m)-57.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB 0.32
EV/EBITDA N/A
EPS(TTM)-2.44
EYN/A
EPS(NY)-2.87
Fwd EYN/A
FCF(TTM)-2.18
FCFYN/A
OCF(TTM)-2.09
OCFYN/A
SpS0
BVpS5.64
TBVpS5.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.98%
ROE -45.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.95%
ROA(5y)-71.69%
ROE(3y)-37.89%
ROE(5y)-107.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 275.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.55
Quick Ratio 10.55
Altman-Z -0.18
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)372.74%
Cap/Depr(5y)383.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.23%
EPS Next Y-17.79%
EPS Next 2Y-8.7%
EPS Next 3Y-4.25%
EPS Next 5Y1.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-55.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-54%
OCF growth 3YN/A
OCF growth 5YN/A